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Acute post-asphyxial encephalopathy around the time of birth remains a major cause of death 
and disability. The possibility that hypothermia may be able to prevent or lessen asphyxial brain 
injury is a “dream revisited”. In this review, a historical perspective is provided from the first 
reported use of therapeutic hypothermia for brain injuries in antiquity, to the present day. The 
first uncontrolled trials of cooling for resuscitation were reported more than 50 years ago. The 
seminal insight that led to the modern revival of studies of neuroprotection was that after 
profound asphyxia, many brain cells show initial recovery from the insult during a short “latent” 
phase, typically lasting approximately 6 h, only to die hours to days later after a “secondary” 
deterioration characterized by seizures, cytotoxic edema, and progressive failure of cerebral 
oxidative metabolism. Studies designed around this conceptual framework showed that mild 
hypothermia initiated as early as possible before the onset of secondary deterioration, and 
continued for a sufficient duration to allow the secondary deterioration to resolve, is associated 
with potent, long-lasting neuroprotection. There is now compelling evidence from randomized 
controlled trials that mild induced hypothermia significantly improves intact survival and 
neurodevelopmental outcomes to mid-childhood.  
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Moderate to severe hypoxic-ischemic encephalopathy (HIE) continues to be a significant cause 
of acute neurologic injury at birth, occurring in approximately 1 to 2 cases per 1000 term live 
births in the developed world (1). The risks are approximately ten-fold higher in the developing 
world (1). The possibility that hypothermia might be able to prevent or lessen asphyxial brain 
injury has been raised since antiquity, and so should be seen as a “dream revisited” (2). 
HISTORICAL OBSERVATIONS 
The earliest recommendations for induced hypothermia can be traced back to the Ancient World. 
The Egyptians, Greeks and Romans first recommended induced cooling for battle-inflicted 
trauma and a variety of cerebral disturbances (3). The Greek physician Hippocrates observed that 
infants exposed in the open survived much longer in winter than summer (4). Many centuries 
later, physiologists such as Claude Bernard and William Edwards first described the effects of 
hypothermia on the human body (5, 6), and observed that asphyxiated newborn kittens continue 
to gasp for longer intervals when actively cooled (5). These observations were later confirmed in 
other animal species (7), and shown to be associated with better functional outcomes after 
cooling during hypoxia. The rationale for these studies was that hypothermic metabolic 
suppression during anoxia prolonged survival (8).  
These early experimental studies noted above focused entirely on the effects of cooling during 
severe hypoxia, which is well known to be associated with dose-related, long-lasting 
neuroprotection (9). The central clinical question is whether cooling after asphyxia or hypoxia-
ischemia is beneficial. 
Early studies of hypothermia in newborn infants 
The apparent protective effects of hypothermia led to small, uncontrolled studies in the 1950s 
5 
and 1960s in which infants who were not breathing spontaneously at 5 minutes after birth were 
immersed in cold water until respiration began and then allowed to spontaneously rewarm over 
many hours (10). Neonatal outcomes were reported to be better than historical controls in over 
200 asphyxiated neonates (11).  
This empiric approach was overtaken by the development of active resuscitation techniques, case 
reports of subcutaneous fat necrosis with calcification after cooling (12), and the higher neonatal 
oxygen requirements and greater mortality rates among premature newborns kept hypothermic 
after birth (13-16). Because of this evidence, there was a pause in investigations of therapeutic 
hypothermia for HIE. 
In this paper we review the resurgence of animal and human research in to mild post-
resuscitation cooling to improve outcomes among infants with HIE. 
PRECLINICAL STUDIES 
The key advance in understanding the pathogenesis of hypoxic-ischemic brain injury was the 
clinical and experimental observation in term fetuses, newborns, and adults that injury to the 
brain is not a single “event” occurring at, or just after, an insult, but rather an evolving process 
that leads to a significant proportion of cell death well after the initial insult, as recently reviewed 
(17). 
Distinct pathophysiological phases have been identified, as illustrated in Figures 1 and 2. The 
actual period of hypoxia and ischemia is the primary phase of cell injury. During this phase, 
there is progressive failure of oxidative metabolism (Figure 1), leading to hypoxic depolarization 
of cells with cytotoxic edema (Figure 2), failure of reuptake and extracellular accumulation of 
excitatory amino acids (excitotoxins) (17). Excitotoxins activate their ion channels and promote 
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additional excessive entry of sodium, water, and calcium into the cells. After return of cerebral 
circulation during resuscitation, cytotoxic edema may transiently resolve over 30 to 60 minutes, 
with at least partial recovery of cerebral oxidative metabolism in a latent phase (18, 19). This 
latent phase that lasts approximately 6 h is characterized by continued EEG suppression, with 
secondary hypoperfusion and suppressed cerebral metabolism (20). This is followed by a 
secondary phase of deterioration (~6 to 15 h after the insult) that may extend over many days. At 
term gestation, this secondary phase is marked by delayed onset seizures, secondary cytotoxic 
edema (Figure 2), accumulation of excitotoxins, failure of cerebral oxidative energy metabolism 
(Figure 1), and ultimately neuronal death (17). 
The studies discussed in this review strongly suggest that the latent or early recovery phase 
represents the key window of opportunity for intervention. 
Factors Determining Effective Neuroprotection with Hypothermia 
Experimentally, the efficacy of neuroprotection with hypothermia is highly dependent on the 
timing of initiation of cooling, its duration, and its depth. 
Cooling during resuscitation and reperfusion 
Brief hypothermia, for 1 to 3 h is modestly neuroprotective, provided it is initiated immediately 
after the insult. For example, after 15 minutes of reversible ischemia in the piglet, mild 
hypothermia (2° to 3°C) for 1 or 3 h reduced neuronal loss 3 days later (21). Protection was lost 
if the brief interval of hypothermia was delayed by as little as 15 to 45 minutes after the primary 
insult (22). Even if such immediate cooling during resuscitation were consistently effective, it is 
presently impossible to reliably identify the infants requiring resuscitation who will go on to 
develop HIE. 
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Immediate or delayed prolonged cooling 
A more recent approach has been to continue hypothermia for longer, throughout the secondary 
phase of deterioration, to suppress delayed encephalopathic processes. Extended cooling for 
between 5 and 72 h appears to be required for protection (23). In unanesthetized postnatal 
day(P)21 rats subjected to hypoxia-ischemia, mild hypothermia (2° to 3°C reduction in body 
temperature) for 72 h immediately after the insult prevented cortical infarction, whereas cooling 
for 6 h did not (24). In P7 rats a greater reduction in body temperature (by 5°C) for 6 h, starting 
immediately after hypoxia-ischemia, improved neurobehavioral recovery after 1 and 6 weeks 
survival (25). Finally, in anesthetized piglets exposed to hypoxia-ischemia, 12 to 48 h of whole 
body cooling by 3.5 or 5°C or head cooling with mild systemic hypothermia started immediately 
after hypoxia prevented delayed energy failure (23), reduced neuronal loss (26), and suppressed 
post-hypoxic seizures (27). Similar results have been reported in adult rodents (28).  
It is interesting to contrast the finding of neuroprotection after 6 h of moderate hypothermia in P7 
rats (25) but not in older rodents or large animals (29). Potentially this might reflect the more 
rapid rate of brain development in rodents than larger animals. However, it is important to 
appreciate that rectal temperatures of healthy nesting neonatal rats are significantly lower than in 
later life (median of 35.4 °C at P7 vs ~38 °C in adults) (30). Thus, P7 rats effectively receive 
continuing mild hypothermia after the acute study period. 
A Window of Opportunity for Treatment 
At present, the window of opportunity for any particular therapy can only be determined 
empirically. The known characteristics of programmed cell death support that earlier initiation of 
interventions after hypoxia-ischemia would be more effective than a later start. Specifically, 
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initiation of neuronal degeneration occurs more slowly after a shorter, less severe period of 
hypoxia-ischemia compared with severe insults (31). However, DNA fragmentation and classic 
ischemic cell change represent only the terminal events of this cascade and are not suitable to 
determine reversibility of tissue injury. In vitro studies distinguished latent and active or 
execution phases during programmed cell death (32). The latent phase is characterized by 
caspase activation (a large family of enzymes that mediate and amplify apoptosis) in the 
cytoplasm, while the active phase involves downstream factors that induce DNA fragmentation 
and chromatin condensation within previously normal nuclei (32). These data suggest that 
activation of downstream, intranuclear factors corresponds with the transition from latent to 
execution (“secondary”) phases of programmed neuronal death (32). 
Systematic in vivo studies support the central importance of starting treatment in the latent phase. 
In near-term fetal sheep, moderate hypothermia induced 90 minutes after reperfusion (i.e. in the 
early latent phase) and continued until 72 h after ischemia prevented secondary cytotoxic edema 
and improved electroencephalographic recovery (33). There was a concomitant, substantial 
reduction in parasagittal cortical infarction and improvement in neuronal loss scores in all 
regions. Only partial protection was observed when initiation of hypothermia was delayed until 
the onset of secondary seizures, 5.5 h after reperfusion (34). No protection was observed with 
further delay (until after seizures were established 8.5 h after reperfusion) (35).  
Consistent with these findings, in adult gerbils, when the delay before initiating a 24-h period of 
cooling was increased from 1 to 4 h after ischemia, neuroprotection in the CA1 field of the 
hippocampus after 6 months of recovery fell from 70 to 12% (36). However, protection was 
almost completely restored by extending the interval of moderate hypothermia (a reduction in 
body temperature of up to 5°C) to 48 h or more, even when the start of cooling was delayed until 
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6 h after reperfusion (37). The optimal duration of hypothermia after delayed initiation of 
cooling appears to be around 72 h. One study in term-equivalent fetal sheep found no further 
improvement in EEG or histological protection when hypothermia was extended from 72 to 120 
h after cerebral ischemia, and possible reduced protection in some regions (38, 39). These data 
are consistent with a recent large randomized controlled trial of extended duration of cooling for 
HIE (40). 
Is Neuroprotection Maintained Long Term? 
There have been reports that mild hypothermia may only delay rather than prevent neuronal loss 
after hypoxia-ischemia in the 7 day old rat (41). This most likely reflects an inadequate duration 
or degree of hypothermia. Subsequent studies both in the 7 day old rat and in adult species 
confirmed that sufficiently prolonged moderate cooling can be associated with persistent 
behavioral and histological protection over weeks or months (17, 25). An additional issue may 
have been rebound hyperthermia in the secondary phase. Even short periods of hyperthermia, 24 
h after either global or brief focal ischemia in the adult rat, exacerbated injury (42), and 
preventing spontaneous delayed pyrexia with antipyretics after post-ischemic hypothermia 
improved histologic protection (43).  
If Some Is Good, Is More Better? 
There appears to be a critical depth of brain and body hypothermia of between 32° and 34°C 
required for effective neuronal rescue. In the fetal sheep undergoing head cooling from 90 
minutes after ischemia, neuroprotection was seen only in fetuses that had a sustained fall of the 
extradural temperature to less than 34°C (normal core temperature in the fetal sheep is 39.5°C) 
(33). In the adult gerbil, 32°C was more protective than 34°C (44).  
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There is a potential trade-off between the adverse systemic effects of cooling, which increase 
below a core temperature of approximately 32 to 34C (45), and cerebral benefits. In newborn 
piglets, reducing body temperature by 8C after hypoxia-ischemia was associated with greater 
metabolic acidosis, increased blood glucose levels, and greater risk of cardiac arrest and death 
compared to cooling by 3.5 to 5C (46). Critically, optimal neuroprotection was seen with 
cooling by 3.5 to 5C (26). A similar therapeutic range has been found in adult dogs after cardiac 
arrest (47). 
Cooling the brain with Head or Body Cooling 
There are temperature gradients within the brain of newborn animals from a warmer core to a 
cooler periphery, such that deep brain temperature is approximately 1° to 2°C higher than the 
surface of the head, 0.7°C higher than core body temperature, and increased during reduced 
perfusion as occurs after severe asphyxia (48). These gradients reflect thermal conduction and 
are affected by tissue heat production and local blood flow.  
Selectively cooling the head could provide neuroprotection with minimal risk of systemic 
adverse effects in sick, unstable neonates. Pragmatically, partially selective cerebral cooling can 
be achieved using a cooling cap applied to the scalp while the body is warmed by an overhead 
heater to limit systemic hypothermia (49). Mild systemic hypothermia is essential during head 
cooling to limit the steepness of the intracerebral gradient and potentially over cool the brain 
periphery while providing cooling of the core. This approach was demonstrated in studies in the 
piglet to achieve a substantial (median, 5.3°C), sustained decrease in deep intracerebral 
temperature at the level of the basal ganglia compared with the rectal temperature (50). Although 
direct brain temperature measurements are not feasible in asphyxiated newborns, head cooling 
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increased the gradient between nasopharyngeal and rectal temperature by nearly 1°C (51). 
Alternatively the brain can be cooled by cooling the body. Brain hypothermia induced by whole 
body cooling results in a more homogenous cooling of the cortex and deeper structures compared 
to head cooling (52). Temperature gradients across the brain of newborn piglets (2 cm depth 
below the cortex to the dura) were similar during cooling to gradients under normal body 
temperature conditions.  
Mechanisms of Action of Hypothermia 
The precise mechanisms of hypothermic neuroprotection are still unclear. Broadly, cooling 
suppresses many of the pathways leading to delayed cell death. Hypothermia reduces cellular 
metabolic demand, excessive accumulation of cytotoxins (e.g., glutamate, (53)) and oxygen free 
radicals during hypoxia-ischemia and inhibits post-ischemic inflammatory reaction and the 
intracellular pathways leading to programmed (i.e. apoptosis-like) cell death (17). 
Cerebral metabolism, excitotoxins, and free radicals 
Hypothermia produces a graded reduction in cerebral metabolism of about 5% for every degree 
of temperature reduction that delays the onset of anoxic cell depolarization (54). However, the 
protective effects of hypothermia even during hypoxia-ischemia are not simply the result of 
reduced metabolism, because cooling improves outcome even when the absolute duration of 
depolarization is controlled (55). Cooling potently reduces post-depolarization release of 
numerous toxins including excitatory amino acids, nitric oxide, and other free radicals, as 
recently reviewed (17). Similarly, cooling begun during reperfusion reduces levels of 
extracellular excitatory amino acids and nitric oxide production in the piglet (53). 
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Extracellular levels of excitatory amino acids rapidly return to baseline values after reperfusion 
(56). Despite normal levels of extracellular glutamate, pathological hyperexcitability of 
glutamate receptors persists for many hours after hypoxia-ischemia in P10 rats, and neuronal 
survival is improved by glutamate receptor blockade (57). In preterm fetal sheep transient 
epileptiform activity was seen in the early post-asphyxial recovery phase, despite a suppressed 
overall EEG, which correlated with the severity of neuronal loss (58). In preterm fetal sheep, 
both post-asphyxial moderate cerebral hypothermia and infusion of a glutamate receptor 
antagonist were partially neuroprotective and associated with marked suppression of epileptiform 
transient activity in the first 6 h after asphyxia (59, 60). The combination of glutamate receptor 
antagonist infusion and hypothermia after severe asphyxia showed non-additive neuroprotection, 
supporting that therapeutic hypothermia is partly protective by attenuating this receptor 
hyperactivity (61). However, hypothermia was associated with greater neuroprotection than 
glutamate blockade, suggesting that additional mechanisms are involved. 
Supporting this, intra-insult hypothermia did not prevent intracellular accumulation of calcium 
during cardiac arrest in vivo, or during glutamate exposure in vitro, as reviewed (17). In contrast, 
in vitro, neuronal degeneration was prevented by cooling initiated after the excitotoxins were 
washed out (17). These data suggest that hypothermia blocks the intracellular consequences of 
excitotoxin exposure. 
Suppression of inflammatory second messengers 
Brain injury leads to induction of the inflammatory cascade with increased release of cytokines 
and interleukins (62). These compounds are believed to exacerbate delayed injury, either by 
direct neurotoxicity and induction of apoptosis or by stimulating endothelial cell 
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proinflammatory responses and leukocyte adhesion and infiltration into the ischemic brain. 
Hypothermia is a potent inhibitor of proliferation, and of superoxide and nitric oxide production 
by microglia, and reduces microglial activation after transient ischemia in the term-equivalent 
fetal sheep (17). These data suggest that hypothermic protection against post-ischemic neuronal 
damage may be, in part, the result of suppression of microglial activation.  
Does hypothermia specifically prevent or suppress programmed cell death? 
Increasing data suggest that hypothermia has a role in suppressing apoptotic processes, 
particularly in the developing brain (17). For example, hypothermia begun after severe hypoxia-
ischemia in the piglet reduced apoptotic cell death but not necrotic cell death, and hypothermic 
neuroprotection in the near-term fetal sheep was closely linked with suppression of activated 
caspase-3 (63). Taken together, these experimental studies suggested that a prolonged duration of 
mild to moderate cerebral hypothermia could improve long-term outcome, if started as soon as 
possible within approximately 6 h of hypoxic-ischemic injury. Based on these extremely 
encouraging data, a number of clinical trials were undertaken. 
CLINICAL TRIALS 
Pilot studies 
Small controlled trials of head cooling with mild systemic hypothermia (51) or whole body 
cooling (64), reported that cooling asphyxiated newborns was both feasible and without obvious 
harm. These studies were not powered to evaluate long-term outcome, but there was some 
suggestion of improved outcomes (65), which was explored in subsequent large trials of efficacy.  
Large Randomized Controlled Trials 
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The encouraging pilot studies supported a series of large trials. A recent Cochrane meta-analysis 
identified 11 randomized controlled trials involving 1505 infants that compared mild induced 
hypothermia to normothermia (66). Hypothermia was associated with a substantial reduction in 
death or moderate or severe neurodevelopmental disability to 18 months of age (relative risk, 
RR, 0.75; 95% confidence interval (CI) 0.68 to 0.83; number needed to treat 7 (5 to 10); 1344 
infants in 8 studies). Cooling was associated with both reduced mortality (RR 0.75; 0.64 to 0.88, 
from 1468 infants in 11 studies) and reduced risk of neurodevelopmental disability in survivors 
(RR 0.77; 0.63 to 0.94, from 917 infants in 8 studies). In 6 trials including 1120 infants, 
hypothermia was associated with a significant increase in normal survival (RR 1.63; 1.12 to 2.7) 
(67-72).  
Improvements were strikingly consistent between these similarly designed trials. All involved 
initiation of cooling within 6 h of birth (cooling was initiated on average between 4 and 5 h), by 
either head cooling with mild systemic hypothermia or mild whole body cooling for up to 72 h. 
For example, in the CoolCap trial, infants with moderate to severe HIE were randomized to head 
cooling with mild systemic hypothermia (rectal temperature 34-35°C, n=116), or conventional 
care (n=118) (67). Death or severe disability at 18 months was reduced in infants with moderate 
amplitude integrated electroencephalographic (aEEG) changes at trial entry (n=172, odds ratio 
(OR) 0.42; 95% CI 0.22-0.80, p=0.009). However, there was no benefit in infants who had 
seizures with profound suppression of the aEEG before cooling was started. The improvement in 
moderately affected infants was primarily related to a more than 50 percent reduction in severe 
neuromotor disability in survivors and improved continuous BSID-II scores, with no change in 
early neonatal mortality.  
Similarly, in a large multi-center trial of whole body cooling from the National Institute of Child 
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Health and Human Development (NICHD), 208 infants were enrolled based on clinical and 
laboratory criteria consistent with exposure to severe perinatal hypoxia plus moderate or severe 
HIE (68). Infants in the experimental group (n=102) were cooled to a rectal temperature of 
33.5±0.5 °C for 72 h using a cooling blanket. The incidence of death or moderate-to-severe 
disability at 18 months was significantly reduced in cooled infants (44%) compared with 
normothermic infants (62%, RR 0.72; 0.54-0.95, P=0.01).  
Subsequent trials had similar results. The Total Body Cooling trial (TOBY) compared body 
cooling to 33.5±0.5°C for 72 h (n=163) to standard care (n=162) (69). There was no significant 
effect on death or disability (RR 0.86; 0.68-1.07, P=0.17) at 18 months of age, but survival 
without neurologic abnormality was improved (RR 1.57; 1.16-2.12, P=0.003). The risk of 
cerebral palsy was reduced in survivors (RR 0.67; 0.47-0.96, P=0.03), with improvements in the 
Mental Developmental Index and Psychomotor Developmental Index of the Bayley Scales of 
Infant Development II.  
Similarly, the neo.nEURO.network trial compared term neonates with HIE randomized to either 
cooling to 33.5±0.05°C with a cooling blanket for 72 h (n=53) followed by slow rewarming or to 
standard care with normothermia (core temperature 37±0.5°C, n=58). All infants were given 
prophylactic analgesia with morphine or fentanyl. There was a significant reduction in death or 
severe disability (51% in the hypothermia group vs 83% in the normothermia group; OR 0.21; 
0.09-0.54, P=0.001), and there were fewer clinical seizures in the hypothermia group. It is 
unknown whether routine sedation contributed to the improvement in this trial.  
The China Study Group studied head cooling with systemic hypothermia to a nasopharyngeal 
temperature of 34±0.2°C and rectal temperature of 34.5–35.0°C for 72 h (n=100) compared to 
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standard care (rectal temperature 36.0–37.5°C, n=94) (70). Cooling was associated with a 
reduced risk of death or disability (31% after cooling vs 49% after standard care; OR: 0.47; 0.26-
0.84, P = 0.01). 
Finally, the Infant Cooling Evaluation (ICE) trial evaluated whole-body cooling, induced by 
turning off the radiant warmer and applying refrigerated gel packs, to achieve a rectal 
temperature of 33.5±0.5°C for 72 h (n=110) or standard care (37° C, n=111) (72). Cooling was 
associated with reduced risk of death or major sensorineural disability at 2 years of age (RR, 
0.77; 0.62-0.98, P=0.03). This study shows that a very simple albeit more labor intensive method 
could be used within strict protocols to induce hypothermia in non-tertiary neonatal settings 
before transport. 
An interesting practical observation from several studies was that mild hypothermia delayed 
recovery of both the aEEG (73), and neurological state (74).  
Long-term follow-up 
There is now evidence that improved outcomes at 18 to 24 months of age are sustained at school 
age. The TOBY trial found greater frequency of survival with an IQ score ≥ 85 at 6 to 7 years 
after treatment with mild hypothermia (52% (75/145), than standard care (39% (52/132); RR 
1.31, P=0.04) (75). Normal survival was increased after hypothermia (45% vs. 28%; RR 1.60; 
95% CI 1.15-2.22), with reduced risk of both cerebral palsy (21% vs. 36%, P=0.03) and 
moderate or severe disability (22% vs. 37%, P=0.03). Similarly, the NICHD trial showed a 
strong trend to reduced risk of either death or an IQ score below 70 at 6 to 7 years of age  (47% 
after hypothermia vs 62% after standard care, P=0.06) (76). These studies support the long-term 
predictive value of a favorable outcome at 18 months of age. 
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Systemic effects of hypothermia 
The studies discussed support that mild hypothermia is generally safe. Meta-analysis suggests 
that hypothermia is associated with a significant increase in thrombocytopenia, but no increase in 
hemorrhagic complications (66). A significant increase in blood pressure has been reported at 
initiation of cooling, both experimentally (34) and clinically (77). This response is mediated by 
rapid peripheral vasoconstriction, i.e. centralization of blood flow (78). Hypothermia also slows 
the atrial pacemaker and intracardiac conduction. Core temperatures less than ~35.5°C are 
associated with mild but sustained sinus bradycardia, not requiring treatment (66). These changes 
are consistent with decreased metabolic demand with decreasing temperature. Some infants show 
markedly prolonged QT duration during cooling (> 98
th
 % corrected for age and heart rate), that 
resolves with rewarming, but no ventricular arrhythmias (79). Thus, therapies that lengthen the 
QT interval should be avoided during cooling.  
Metabolically, hypothermia has been associated with transient mild hyperglycemia, both in 
adults (80) and infants (67), but no increase in the rate of hypoglycemia. A similar transient rise 
in glucose concentrations has been observed in the piglet and near-term fetal sheep (33, 46), and 
likely reflects hypothermia-induced catecholamine release. Head cooling was associated with 
scalp edema under the cap, which resolved rapidly before or after removal of the cap (67). 
Conversely, there was an apparent reduction in the incidence of elevated liver enzymes in the 
cooled group (38% of cooled infants vs. 53% of controls, p=0.02) (67). Hypothermia has 
profound anti-inflammatory effects and in older adults seems to increase the risk of infective 
complications such as pneumonia and bacteremia (81). There is no evidence of increased risk of 
infection in the newborn studies, but this may reflect prophylactic antibiotic treatment (67, 68).  
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All the clinical trials to date involved infants ≥ 35-36 weeks gestation. It is unknown whether 
selected preterm infants with evidence of acute metabolic acidosis on cord blood and clinical 
encephalopathy would also benefit from hypothermia. Studies in preterm fetal sheep, at an 
equivalent stage of neural maturation found that head cooling, started 90 minutes after profound 
asphyxia, reduces white and grey matter loss (58). The NICHD Neonatal Research Network has 





 weeks (NCT01793129).  
Conclusions 
There is now overwhelming clinical and experimental evidence that mild to moderate post-
asphyxial cerebral cooling is associated with long-term improved survival without disability. The 
key requirements for neuroprotection are that hypothermia be initiated as soon as possible in the 
latent phase, within the first 6 h, before secondary deterioration, and that it be continued for a 
sufficient period in relation to the evolution of delayed encephalopathic processes, typically 
around 72 h. These findings are now supported by large randomized trials of both head cooling 
combined with mild systemic hypothermia and whole body cooling that found that cooling is 
safe, at least in the intensive care environment, and associated with a significant improvement in 
survival without disability. These studies show that as currently applied approximately 15% of 
infants will have better outcome after cooling compared to standard care (66). Future studies to 
improve outcomes should now be conducted in the setting of mild induced cooling as the 
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Figure 1. Schematic diagram showing the phases of primary and secondary energy failure after 
hypoxia-ischemia on magnetic resonance spectroscopy (MRS), and the amelioration of 
secondary energy failure with therapeutic hypothermia started during the latent phase after 
transient hypoxia-ischemia in a newborn piglet. Upper panel shows phosphorus-31 MRS 
NTP/EPP peak area ratio at baseline, during and after hypoxia-ischemia. The preservation of 
high energy phosphates with hypothermia versus normothermia is shown on the diagram (blue 
line versus red line) and in the representative spectra at 48 h (red normothermia, blue 
hypothermia). Lower panel shows proton MRS lactate/NAA peak area ratio at baseline, and 
during and after hypoxia-ischemia. The amelioration of the rise in lactate/NAA with 
hypothermia versus normothermia is shown on the diagram (blue line versus red line) and in the 
representative spectra at 48 h (red normothermia, blue hypothermia).  NTP: nucleotide tri-
phosphate; EPP: exchangeable phosphate pool; NAA: N-acetyl aspartate. 
Figure 2. The effect of hypothermia started 3 h after a 30 minute period of cerebral ischemia in 
term-equivalent fetal sheep (38). The period of ischemia is shown by the dashed arrow. Cooling 
is shown by the filled blue bar. The top panel shows changes in extradural temperature (°C) after 
sham ischemia (open circles), ischemia-normothermia (solid black circles) and ischemia-
hypothermia (inverted blue triangles). The lower three panels show changes in cortical 
impedance (%) a measure of changes in cell swelling (cytotoxic edema), change in 
electroencephalographic (EEG) power (dB, decibels) and change in the spectral edge frequency 
of the EEG (SEF, Hz). The hypothermia group shows complete suppression of the secondary rise 
in impedance, greater recovery of EEG power after resolution of delayed seizures (which occur 
31 
from approximately 9 to 72 h) and improved SEF that persists after rewarming. Data are mean ± 
SEM. 
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